Mucomucil (Acetylcysteine)

Acetylcysteine breaks disulfide bonds in mucus glycoproteins, reducing viscosity and promoting clearance from the airways. In acetaminophen toxicity, it supplies cysteine for glutathione synthesis, enabling detoxification of the harmful metabolite N‑acetyl‑p‑benzoquinone imine.

The dose of Mucomucil is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and local treatment guidelines. No standard dosing is provided here.

The pregnancy category for acetylcysteine is not definitively established. It should only be used during pregnancy or lactation when the potential benefit outweighs any possible risk, and after careful evaluation by the treating physician.

To place an order, submit an enquiry on the Mucomucil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with oral mucolytics such as carbocisteine, intravenous acetylcysteine delivers rapid systemic concentrations, making it suitable for severe airway obstruction or emergency acetaminophen overdose. Its dual action on mucus viscosity and glutathione replenishment distinguishes it from agents that only affect mucus properties.

Mucomucil must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the administration protocol.

Mucomucil is given by intravenous infusion. The exact infusion rate and duration are set by the prescriber, often starting with a loading dose followed by a maintenance infusion, and administered under clinical supervision to monitor for adverse reactions.

The most serious risks include anaphylactoid reactions such as bronchospasm, urticaria, angioedema, and severe hypotension. Prompt recognition and treatment are essential; emergency measures should be readily available during infusion.

Mucomucil should be avoided in patients with known hypersensitivity to acetylcysteine or any excipients, in those with uncontrolled asthma or reactive airway disease prone to bronchospasm, and in individuals receiving nitroglycerin where additive hypotensive effects could be hazardous.